📝 Kwality Pharmaceuticals Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Kwality Pharmaceuticals Ltd reported revenue of ₹162 crore for the quarter ended June 2026 (Q1 FY27), up 46.3% from ₹111 crore in the same quarter last year, and up 3.4% sequentially over the March 2026 quarter.
Net profit rose 113.5% year-on-year to ₹26 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹24.69.
Operating profit stood at ₹41 crore — an operating margin (OPM) of 25.3%, compared with 21.6% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Kwality Pharmaceuticals Ltd posted revenue of ₹502 crore, a growth of 35.7% over FY25, with a net profit of ₹67 crore (up 71.8% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹553 crore with a net profit of ₹81 crore.
Valuation snapshot
At the current price of ₹3,348.05, 539997 has a market capitalisation of ₹3,525 crore and a trailing P/E of about 43.7.
Within the Pharmaceuticals industry, it is the 4th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 54.87%, foreign institutional investors (FIIs) 2.79%, domestic institutional investors (DIIs) 0.36%, public shareholders 41.99% of Kwality Pharmaceuticals Ltd.